H.R. 7506 · 117th Congress
New Era of Preventing End-Stage Kidney Disease Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
ButterfieldSponsor13 cosponsors · 9 D, 4 R
R
Bilirakis
SB
D
Bishop
ML
D
Levin
DR
D
Ross
SW
D
Wild
ZL
D
Lofgren
DP
D
Phillips
BP
R
Posey
MB
R
Burgess
KS
D
Schrader
SP
D
Peters
DC
R
Crenshaw
DD
D
Davis1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill addresses rare kidney diseases through research, training for health professionals, and other means. It also modifies requirements for Medicare drug plan formularies that include drugs for rare diseases or conditions.
What it does: CRS summary · Introduced in House · Apr 14, 2022
New Era of Preventing End-Stage Kidney Disease Act
This bill addresses rare kidney diseases through research, training for health professionals, and other means. It also modifies requirements for Medicare drug plan formularies that include drugs for rare diseases or conditions.
The Department of Health and Human Services (HHS) must
- convene a conference focused on diagnosis and treatment of rare kidney diseases;
- study risk factors, access to care (including to genetic and genomic testing), and other matters related to rare kidney diseases; and
- establish grants for supporting kidney disease education and referrals in communities of color.
HHS may award grants to educate and train health professionals about kidney disease and nephrology. Additionally, health professional schools that receive certain HHS funding for educating underrepresented minority individuals must support postgraduate nephrology training.
The National Institutes of Health (NIH) must report on diversity in its kidney disease research. The NIH may also (1) support research on rare kidney diseases that, among other requirements, includes persons of color in study populations; and (2) establish regional centers of excellence for rare kidney diseases.
The Centers for Medicare & Medicaid Services must evaluate methods for (1) treating rare kidney diseases, with a focus on delaying dialysis and transplant; and (2) raising awareness about rare kidney diseases, including in communities of color.
Furthermore, if a Medicare drug plan formulary includes a drug to treat a rare disease or condition, at least two members of the committee that develops or reviews the formulary must have expertise in the field of medicine related to that drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: New Era of Preventing End-Stage Kidney Disease Act
Latest action (Apr 15, 2022): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Apr 14, 2022
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.